Liangjun Yang
Zheng Fang1
Jiajie Zhu
Bo Yang- 1Department of Gastroenterology, Tongde Hospital of Zhejiang Province (Zhejiang Academy of Traditional Chinese Medicine), Hangzhou, China
- 2Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
- 3Department of Pharmacy, Tongde Hospital of Zhejiang Province (Zhejiang Academy of Traditional Chinese Medicine), Hangzhou, China
- 4Endoscopy Center, Tongde Hospital of Zhejiang Province (Zhejiang Academy of Traditional Chinese Medicine), Hangzhou, China
Sijunzi Decoction (SJZD) is a traditional Chinese medicine formula widely used in the treatment of gastrointestinal disorders. Clinical studies have substantiated the efficacy of SJZD in managing conditions such as functional dyspepsia, chronic gastritis, gastric cancer, irritable bowel syndrome, colorectal cancer, and ulcerative colitis. Despite its proven effectiveness, the precise mechanisms by which SJZD operates remain incompletely understood. In this study, we undertake a systematic review of both the clinical applications and the mechanistic underpinnings of SJZD in the context of gastrointestinal disease treatment. Research indicates that SJZD functions through a spectrum of mechanisms including the regulation of intestinal flora, alleviation of inflammation, modulation of immune responses, and facilitation of mucosal repair in the treatment of gastrointestinal ailments. This comprehensive analysis aims to provide a clearer understanding of how SJZD benefits patients with gastrointestinal disorders.
Introduction
The digestive system, which consists of the gastrointestinal tract, liver, pancreas, and gallbladder, facilitates the digestion of food—a crucial process that converts food into nutrients used by the body for energy, growth, and cellular repair. Gastrointestinal diseases, such as functional gastrointestinal diseases, inflammatory bowel disease, and tumors, significantly impact a large segment of the population, leading to a range of uncomfortable symptoms, increased morbidity, and substantial healthcare costs (Peery et al., 2015). Gastrointestinal diseases are prevalent, with an estimated prevalence rate of 16% for functional dyspepsia (FD) (Ford et al., 2020), over 50% for chronic gastritis (Sipponen and Maaroos, 2015), and 9.2% for irritable bowel syndrome (IBS) (Oka et al., 2020). The inflammatory bowel diseases, primarily including Crohn’s disease and ulcerative colitis (UC), are chronic inflammatory disorders of the gastrointestinal tract. In China, there has been a significant increase in the prevalence and incidence of inflammatory bowel disease over the past 3 decades, which provides challenges for the medical field (Park and Cheon, 2021). Additionally, among gastrointestinal malignancies in China, colorectal and gastric cancers rank second and fifth in terms of incidence, while they rank third and fourth in mortality, respectively (Han et al., 2024). Overall, digestive diseases remain a major contributor to the global healthcare burden, with little to no decline in prevalence or incidence observed in recent years (Wang et al., 2023). Given the substantial impact of these conditions, intervention in patients with digestive diseases is critically important for alleviating symptoms and enhancing their quality of life. However, developing effective drug-based therapies for gastrointestinal diseases presents considerable challenges, particularly due to the unclear etiology of many of these disorders (Halama and Haberkorn, 2020; Mishra et al., 2020; Singh et al., 2022). Addressing this complexity is essential for improving patient outcomes and managing the growing burden of gastrointestinal diseases in the healthcare system.
Traditional Chinese medicine (TCM), developed in China, is an ancient system that extensively examines human physiology, pathology, disease diagnosis, and treatment, with a rich historical background of effectively addressing digestive disorders. Central to this practice is the use of herbal medicine, which is regarded as a vital approach for managing a range of conditions, including functional gastrointestinal diseases (Tan et al., 2020), inflammatory bowel disease (Zhang S. et al., 2022), and malignancies such as gastric and colorectal cancers (Chen J.-F. et al., 2023; Dai Z. et al., 2024). Sijunzi decoction (SJZD), a classical formula in TCM, is composed of four Chinese herbs: Panax ginseng C. A. Mey. (or Codonopsis radix.), Wolfiporia cocos (F.A. Wolf) Ryvarden and Gilb., Atractylodes macrocephala Koidz., and Glycyrrhiza uralensis Fisch. ex DC. In the SJZD, P. ginseng C. A. Mey. (or C. radix.) takes the role of the Emperor herb, being the primary ingredient for replenishing Qi and strengthening the spleen and stomach. Atractylodes macrocephala Koidz. acts as the Minister herb, supporting the spleen and drying dampness to amplify C. radix‘s effects on Qi and spleen reinforcement. Wolfiporia cocos (F.A. Wolf) Ryvarden and Gilb. is the Assistant herb, which works in conjunction with A. macrocephala Koidz. to further strengthen the spleen and eliminate dampness. Lastly, G. uralensis Fisch. ex DC. serves as the Messenger Herb, harmonizing the middle, supplementing Qi, and coordinating the actions of the other herbs within the formula. Together, these four herbs create a balanced and effective composition for tonifying the spleen and stomach.
This formulation has been widely utilized to address spleen deficiency, which presents symptoms such as anorexia, diarrhea, loose stools, and systemic discomforts including fatigue, weakness in the limbs, and cold extremities. A randomized, double-blind, placebo-controlled, multi-center clinical trial has demonstrated that SJZD can alleviate fatigue symptoms and enhance overall health status in patients with chronic fatigue syndrome (Dai L. et al., 2024). SJZD is primarily used to treat gastrointestinal diseases, including chronic gastritis, functional gastrointestinal disorders, UC, and gastrointestinal carcinomas, based on its effects of strengthening the spleen and replenishing Qi in accordance with TCM theory. Over the past 2 decades, an increasing number of clinical studies have reported the application of SJZD in patients with gastrointestinal diseases. Concurrently, a series of experimental studies have been conducted to elucidate the mechanisms by which SJZD treats gastrointestinal diseases. However, the clinical application, pharmacodynamics, and molecular mechanisms of SJZD in the treatment of gastrointestinal diseases have not yet been systematically analyzed, and the common points of SJZD in gastrointestinal diseases have not been revealed. In this article, we review and summarize previous clinical and experimental studies on SJZD for gastrointestinal disorders, as well as insights into its pharmacological effects, aiming to illustrate the advantages and promote the application of TCM in the treatment of gastrointestinal diseases.
Methodology
In this review, we aim to summarize and evaluate recent evidence primarily drawn from clinical and experimental research, as well as systematic reviews, regarding the efficacy of SJZD in the treatment and management of gastrointestinal disorders. A comprehensive literature search was conducted, focusing mainly on publications from PubMed and ScienceDirect, limited to articles written in English. The keyword “sijunzi” was employed for searches on both databases.
The inclusion criteria encompassed evidence from randomized controlled trials, systematic and narrative reviews, observational studies, nonclinical studies, case reports, and expert opinions published over the past 24 years (2000–2024). In contrast, study protocols, duplicate articles, and conference abstracts were excluded from consideration.
Sijunzi decoction
As an empirical decoction, Sijunzi decoction was recorded in the Taiping Huimin Hejiju Fang of the Song Dynasty (published around 1110 A.D.). It consists of P. ginseng C. A. Mey. (Renshen) or C. radix (Dangshen), W. cocos (F.A. Wolf) Ryvarden and Gilb. (Fuling), A. macrocephala Koidz. (Baizhu), and G. uralensis Fisch. ex DC. (Gancao).
Panax ginseng C. A. Mey. is one of the most important traditional herbs and healthy foods in East Asian herbal remedies, with a history spanning over 2,000 years. The roots and rhizomes of P. ginseng C. A. Mey. are utilized in traditional medicine to treat diseases by replenishing Qi (Zhang et al., 2024). Modern research has identified the main chemical components of ginseng, which primarily include ginsenosides, ginseng polysaccharides, and ginseng polypeptides. Pharmacological studies indicate that ginseng possesses strong anti-inflammatory and immunoregulatory effects in the intestinal system (Zhao et al., 2024). Additionally, a meta-analysis has demonstrated that ginseng consumption is associated with a significantly reduced risk of gastric and colorectal cancer (Jin et al., 2016). This may be due to ginseng’s ability to inhibit the proliferation, growth, invasion, and metastasis of tumor cells, induce tumor cell apoptosis, and ultimately suppress tumor initiation and progression (Ni et al., 2022; Zhao et al., 2022).
Codonopsis radix is an herb that has historically been used as a cost-effective substitute for the more expensive P. ginseng C. A. Mey. As a widely recognized medicinal plant in the field of TCM, C. radix possesses the ability to replenish Qi, strengthen the spleen, and nourish the blood. This herb contains a diverse array of chemical constituents, including flavonoids, polyacetylenes, triterpenes, steroids, alkaloids, resinous substances, and other biologically active compounds. Substantial evidence demonstrates that C. radix exhibits diverse biological activities, including immunomodulatory, antitumor, anti-inflammatory, and anti-fatigue properties (Luan et al., 2021). Furthermore, extracts of C. radix possess extensive pharmacological properties, such as protecting the gastrointestinal mucosa, exhibiting anti-ulcer effects, demonstrating antitumor activity, regulating endocrine functions, improving hematopoietic activity, and providing cardiovascular protection (Dong et al., 2023).
Wolfiporia cocos (F.A. Wolf) Ryvarden and Gilb, commonly known as Poria cocos, is a well-known fungus that has been used as a traditional medicine and functional food in China for over 2,000 years. The primary bioactive constituents of Poria cocos include polysaccharides, triterpenoids, steroids, fatty acids, and enzymes. Clinically, it is used to treat spleen-deficiency syndrome, often accompanied by symptoms such as digestive disorders, diarrhea, indigestion, and vomiting. Numerous studies have demonstrated that Poria cocos offers several beneficial effects, including intestinal protection, modulation of intestinal flora, anti-inflammatory, and antitumor activity (Zou et al., 2021; Wang et al., 2022). As a result, it is considered effective in the treatment of conditions such as IBS (Yang et al., 2023), colitis (Lan et al., 2023), and gastric cancer (Wang et al., 2022).
The rhizomes of A. macrocephala Koidz. have traditionally been utilized to invigorate the spleen and replenish qi for the treatment of various diseases. The primary chemical constituents of A. macrocephala Koidz. include terpenoids, polysaccharides, alkynes, flavonoids, and steroids. A significant body of research has highlighted the beneficial effects of A. macrocephala Koidz. on gastrointestinal diseases. Studies have confirmed that A. macrocephala Koidz. and its extracts possess multiple pharmacological activities, including immune enhancement (Xiang et al., 2020), antitumor (Liu et al., 2022), antioxidant (Bailly, 2021), and anti-inflammatory effects (Gu et al., 2019), which have therapeutic potential for gastrointestinal tumors (Chen T. et al., 2023; Choi et al., 2024b), chronic gastritis (Yang S. et al., 2020), UC (Cheng et al., 2023), and IBS (Choi et al., 2024a).
The dried roots and rhizomes of G. uralensis Fisch. ex DC., commonly known as Gan-Cao in Chinese, are widely used as herbal medicine worldwide. It is regarded as an “essential herbal medicine” in TCM due to its ability to reduce toxicity and enhance the effectiveness of other medicinal plants when used in combination. The primary chemical constituents of licorice include triterpenoid saponins, flavonoid glycosides, free phenolic compounds, polysaccharides, coumarins, and alkaloids. Currently, it is extensively employed in the treatment of respiratory, liver, and gastrointestinal diseases, owing to its hepatoprotective, anti-inflammatory, antiviral, and antioxidant properties (Jiang et al., 2020; Li et al., 2020).
In summary, the herbs in SJZD exhibit a wide range of pharmacological activities, including immunomodulation, antitumor effects, anti-inflammatory properties, and gastrointestinal protection, thereby addressing a spectrum of gastrointestinal disorders and contributing to the overall health.
Sijunzi decoction in upper gastrointestinal disorders
Functional dyspepsia
FD, located in the gastroduodenal region, is among the most common functional gastrointestinal disorders. The prevalence of FD has been steadily increasing, significantly impacting patients’ quality of life. The main contributing factors to FD include abnormal gastrointestinal dynamics, heightened visceral sensitivity, Helicobacter pylori infection, disturbances in intestinal flora, and psychological influences. This disorder is characterized by a diverse range of clinical manifestations, such as early satiety, postprandial fullness, and epigastric pain or burning, which seriously affect patients’ quality of life and impose a heavy social and economic burden. In modern medicine, the treatment options for FD predominantly involve gastrointestinal motility agents, therapies aimed at alleviating visceral hypersensitivity, and medications targeting anxiety and depression. However, the efficacy of these treatments remains unsatisfactory (Lacy et al., 2023). TCM is a promising alternative, offering a holistic approach that may provide specific advantages in addressing the complex nature of FD. Based on the symptomatology of functional dyspepsia in TCM, it is commonly described as “distension and fullness,” “stomach pain,” and “retention” (Speciality Committee of Digestive DiseasesChinese Association of Integrative Medicine, 2011). Meta-analysis has shown that TCM formulas tend to yield better outcomes in alleviating overall dyspeptic symptoms (Chu et al., 2018). According to TCM, SJZD has been utilized in accordance with Chinese medicine for managing symptoms of indigestion. A meta-analysis has shown that SJZD-based prescriptions could be effective in treating FD, with no significant adverse effects detected (Wang Y. et al., 2021). However, due to the potential for bias, further validation of the benefits of SJZD for FD treatment necessitates the implementation of standardized, large-scale, and rigorously designed RCTs. These findings suggest that SJZD-based therapies hold promising potential for treating FD.
Chronic gastritis
Chronic gastritis is a chronic inflammatory response of the gastric mucosa that can be attributed to various factors such as H. pylori infection, medication usage, stress, and autoimmune processes. Generally, it presents as bloating, epigastric pain, indigestion, appetite loss, and other symptoms, considerably compromising patients’ quality of life and increasing their susceptibility to developing cancer (Quan et al., 2018). Despite its prevalence, therapeutic approaches for chronic gastritis primarily focus on symptomatic treatment, as no specific Western medicine has been identified, particularly for chronic atrophic gastritis (Yan-Rui et al., 2024). Studies have confirmed that TCM is effective in alleviating the clinical symptoms of patients with chronic gastritis and can also impede the progression of chronic atrophic gastritis towards gastric cancer (Qin et al., 2013; Yang L. et al., 2020). As a classic TCM decoction, a clinical study has proved that SJZD can significantly improve the scores of the histopathology of chronic gastritis and H. pylori clearance rate (Gan et al., 2017). Additionally, several scholars have employed a modified version of SJZD for the treatment of chronic atrophic gastritis, and their findings indicate the efficacy of modified SJZD in alleviating fatigue and tiredness symptoms among chronic atrophic gastritis patients (Tian et al., 2019). Furthermore, a meta-analysis has shown that SJZD is an effective treatment option for chronic atrophic gastritis, as it improves clinical outcomes, enhances quality of life, and increases the eradication rate of H. pylori, as well as levels of GAS-17, PGI, and PGR in patients with chronic atrophic gastritis (Huang and Shao, 2024).
High gastric acid secretion is correlated with the manifestation of discomforting symptoms in individuals with chronic gastritis. In vitro experiments have substantiated the antacid properties of SJZD (Wu et al., 2010), suggesting a potential link to alleviating the distressing symptoms of this condition. Additionally, through network pharmacology analysis, it has been predicted that SJZD may alleviate chronic gastritis by suppressing the inflammatory response of peripheral blood leukocytes. Subsequent experimental studies have further validated the efficacy of SJZD in ameliorating both local gastric inflammation and inflammation in peripheral blood leukocytes (Wang et al., 2020). Gastric precancerous lesions are considered to be crucial steps in the progression from chronic atrophic gastritis to gastric cancer. Early identification, management, and surveillance of gastric precancerous lesions are imperative for preventing gastric cancer. According to proteomics and metabolomics analyses, research has demonstrated that SJZD possesses the capacity to hinder the progression of gastric precancerous lesions by regulating oxidative phosphorylation (Zhu et al., 2024). Additionally, modified formulas derived from SJZD, such as Weipiling decoction (Yang et al., 2022) and Weiwei decoction (Hong et al., 2024), have exhibited specific therapeutic effects in managing precancerous gastric lesions. These results demonstrated that SJZD is effective in the treatment of chronic gastritis.
Gastric cancer
Gastric cancer, a leading cause of cancer-related deaths globally, is ranked as the fifth most prevalent malignant tumor worldwide (Thrift et al., 2023). Despite advancements in stomach cancer treatment in recent years, the mortality rate associated with this disease remains significant. Hence, finding novel therapeutic approaches for gastric cancer holds exceptional significance. TCM is widely used in gastric cancer patients, especially in Asia. A retrospective cohort study conducted in Taiwan from 1997 to 2010 indicates that Chinese herbal medicine enhances the overall survival of gastric cancer patients (Hung et al., 2017). These findings establish a foundation for future research exploring the effectiveness of TCM as a therapeutic approach for gastric cancer.
SJZD has been widely utilized as a therapeutic approach for the long-term treatment of gastric cancer. A retrospective analysis has demonstrated that combining enteral nutrition with SJZD can effectively treat precachexia in cancer patients through the alleviation of inflammatory response, improvement of nutritional status, and enhancement of performance (Li et al., 2021). Additionally, a meta-analysis was conducted to evaluate the efficacy and safety of SJZD combined with enteral nutrition in GC patients, resulting in significant improvements in albumin, prealbumin, transferrin, immunoglobulin, CD3+, CD4+, and CD4+/CD8+ (Chen et al., 2020). Furthermore, treatment with SJZD inhibited cell growth and triggered apoptosis in gastric cancer cells. This effect was achieved by suppressing the expression of gastric cancer stem cell markers, as well as by reducing the nuclear accumulation and DNA binding activity of β-catenin (Jia et al., 2018; Li Y.-J. et al., 2022). CMTM2, an immune-related gene within the CMTM family, plays a significant role in tumor progression, and prognosis in gastric cancer (Qian et al., 2020). In vitro investigations reveal that SJZD markedly attenuates the proliferation, migration, invasion, and cancer stem cell-like characteristics of gastric cancer cells through the upregulation of CMTM2 expression (Li X. et al., 2022). Network pharmacology analysis predicted that SJZD may exert anti-gastric cancer effects via a comprehensive mechanism involving multiple compounds, targets, and pathways. Subsequent experimental findings have supported these predictions, demonstrating that SJZD can effectively suppress tumor growth and induce apoptosis in gastric tumor cells. These effects are mediated by the downregulation of key genes such as VEGFA, iNOS, COX-2, and Bax/Bcl2, as well as the inhibition of p-PI3K and p-AKT expression levels (Ding et al., 2022). Overall, the integrated approach of network pharmacology and experimental validation highlights the potential of SJZD as a therapeutic option for gastric cancer treatment.
Sijunzi decoction in lower gastrointestinal disorders
Irritable bowel syndrome
IBS is a chronic functional gastrointestinal disorder that presents with abdominal pain related to defecation or alterations in bowel habits. IBS is characterized by various gastrointestinal symptoms, including bloating, abdominal pain, urgency, and diarrhea or constipation, along with altered bowel habits, without any organic abnormalities. The conventional management of IBS typically includes lifestyle modifications, dietary interventions, and pharmacological treatments. Pharmacological treatment options include the regulation of gastrointestinal motility, supplementation with probiotics and prebiotics, as well as the use of antidepressants. However, the effectiveness of these treatments is frequently found to be unsatisfactory (Huang et al., 2023). TCM has shown effectiveness in treating IBS, addressing clinical symptoms such as abdominal pain, distension, and bowel habits, while also improving quality of life. As a promising approach, TCM has the potential to target dysmotility, visceral hypersensitivity, and the gut-brain axis by increasing NPY levels and reducing serotonin, making it a viable option for treating IBS (Xiao et al., 2015; Liu et al., 2023).
SJZD has been utilized in the treatment of IBS, specifically IBS with diarrhea (IBS-D). A meta-analysis revealed that the combined use of modified SJZD and Tongxie Yaofang significantly enhanced the overall clinical effectiveness rate for IBS-D when compared to conventional Western medicine treatments (Yan et al., 2023). The gut microbiota, functioning as a distinct organ with well-defined roles, plays a pivotal role in the development and severity of IBS. Alterations in the microbiota composition are significant factors contributing to the persistence of IBS symptoms (Canakis et al., 2020). Experimental evidence has demonstrated that a purified homogeneous polysaccharide obtained from SJZD exhibits immunomodulatory effects by modulating the abundances of nine genera of intestinal bacteria (Gao et al., 2018). To investigate the specific interactions between SJZD and the intestinal microbiota-derived from patients with IBS-D, an in vivo cocultivation system was created. The findings demonstrated that SJZD effectively restored the dysbiosis of the intestinal microbiota and improved the disrupted neurotransmitter metabolism associated with the key symptoms of IBS-D (Xia et al., 2022). In summary, SJZD exhibits therapeutic potential for treating IBS-D by modulating gut microbiota, thereby underscoring its efficacy in comparison to traditional treatments.
Colorectal cancer
Colorectal cancer ranks as the third most prevalent cancer and the second leading cause of cancer-related deaths worldwide. While the incidence and mortality rates of colorectal cancer have decreased in recent decades, epidemiological studies indicate a potential increase in its occurrence among individuals under the age of 50 (Thanikachalam and Khan, 2019). Considering that the symptoms of the disease typically only manifest in the advanced stage, the implementation of active screening and treatment represents an effective approach to diagnose and treat the condition. The primary treatments for colorectal cancer currently include surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. However, challenges such as surgical complications, chemotherapy resistance, toxic side effects, and elevated rates of metastasis and recurrence significantly compromise patients’ quality of life (Pilkington et al., 2022). Consequently, research into more effective treatment options has become a focal point in this field. Chinese medicine has been utilized in the treatment of colorectal cancer. A cohort study conducted in China revealed that Chinese herbal medicines might mitigate the risk of recurrence and metastasis in patients with stage II and III colorectal cancer (Tang et al., 2022). This emerging evidence highlights an important frontier in the fight against colorectal cancer, suggesting that integrative treatment strategies incorporating TCM could significantly enhance patient prognosis and improve quality of life.SJZD has been used as a classical decoction in the treatment of digestive malignant tumor (Wu and Xuan, 2007). Through network pharmacology analysis, researchers have discovered that SJZD exerts its therapeutic effects on colorectal cancer by modulating multiple targets and pathways. A study specifically investigated the core genes involved in the therapeutic mechanism of SJZD for colorectal cancer, revealing that SJZD influences protein binding in colon cancer by altering the expression of HSPB1, IGFBP-3, and SPP1 (Du et al., 2022). Furthermore, in vitro and in vivo experiments have confirmed that SJZD can induce apoptosis and autophagy in colorectal cancer cells through the PI3K/Akt/mTOR pathway (Shang et al., 2023). To identify potential therapeutic targets of SJZD, microarray analysis was conducted on patients with colorectal cancer who were undergoing treatment with SJZD. The results indicated that KLF4, which showed a significant correlation with reduced overall survival and recurrence rates, may serve as a potential therapeutic target of SJZD for the treatment of colorectal cancer (Jie et al., 2017). NK cells play a crucial role in cancer immunosurveillance by targeting and killing tumor cells, holding great potential for the therapy of gastrointestinal cancers (Wang F. et al., 2021). A study has shown that SJZD enhances the expression levels of death receptor 4 and death receptor 5 through modulation of P53 expression. This increase in receptor levels consequently enhances the sensitivity of colon cancer cells to NK cell-mediated killing, resulting in the inhibition of colon cancer growth (Wang et al., 2024). The liver is a frequent site of metastasis for colon cancer. A study has proved that modified SJZD demonstrates the ability to inhibit liver metastasis in colon cancer by activating the innate immune system (Zhou et al., 2019). These findings offer a potential complementary and alternative therapy for colon cancer.
Ulcerative colitis
UC is a multifaceted, chronic immune-mediated inflammatory bowel disease that typically initiates in the rectum and can progress proximally to affect the entire colon (Feuerstein et al., 2019). Common symptoms exhibited by UC patients include frequent bowel movements, presence of mucus and pus, blood in stool, diarrhea, abdominal pain and discomfort, tenesmus, as well as weight loss. Conventional treatments for UC—such as corticosteroids, amino-salicylates, immunomodulatory agents, and biological therapies—are widely utilized in clinical practice. However, these medications have significant limitations, particularly due to their undesirable side effects (Kucharzik et al., 2020). In TCM, UC is classified under the “dysentery” category based on its symptomatology. Clinical research has shown that TCM granules are superior to placebo in inducing clinical remission and promoting mucosal healing among patients with moderately active and 5-ASA-refractory UC (Shen et al., 2021). Recent studies investigating the mechanisms by which TCM treats UC have been steadily increasing. These studies indicate that TCM can effectively inhibit the onset and progression of UC through its anti-inflammatory and antioxidant properties, while also modulating the body’s immune response and other related factors (Zheng et al., 2022).
As a classical Chinese herbal formula, SJZD has been extensively utilized and clinically proven effective in the treatment of UC. Research findings have revealed that SJZD restores the microbial homeostasis and intestinal barrier integrity in UC by inhibiting the abundance of the phylum Proteobacteria and the genus Escherichia-Shigella, alleviating colon tissue damage, and enhancing the expression of tight junction proteins (Wu et al., 2023). The mucosal epithelium plays a crucial role in maintaining the balance of the intestinal ecosystem. Experimental studies have shown that SJZD exhibits a protective effect on the intestinal barrier against TNBS-induced colitis in rats and TNBS-damaged Caco-2 cells in vitro (Lu et al., 2017). As an essential substrate for nucleotide synthesis in epithelial cells and a major energy source, l-glutamine is widely used in the treatment of gastrointestinal diseases to alleviate mucositis. Research has demonstrated that the combination of l-glutamine with SJZD is more effective than using l-glutamine alone in ameliorating the severity of diarrhea, histopathological damage, and the disruption of villus and crypt structures in the intestinal mucosa following continuous 5-Fu injections in mice (Qu et al., 2020). As an immune-mediated inflammatory disorder affecting the colon, immune dysregulation plays a crucial role in the pathogenesis of UC. To investigate the impact of SJZD on the immune system in UC, a research study was conducted. The findings demonstrated that SJZD effectively ameliorated the DSS-induced inflammatory response in UC rats by increasing the content of secretory IgA in the intestinal mucosa and elevating the levels of IL-2 in the intestinal tissue (Yu et al., 2016). In summary, SJZD primarily exerts its effect in the treatment of UC by promoting mucosal repair and regulating mucosal immune function.
Pharmacological mechanisms of SJZD for the treatment of gastrointestinal disorders
Over the past few decades, a variety of in vivo and in vitro experimental studies have enhanced our understanding of the mechanisms underlying the effectiveness of SJZD in treating gastrointestinal disorders. This section offers a summary of the different mechanisms of action, which encompass regulating intestinal flora, reducing inflammation, modulating the immune response, and promoting mucosal repair (Figure 1). Table 1 shows detailed information of the pharmacological studies carried out on SJZD.
Figure 1. The mechanism of action of SJZD in the treatment of gastrointestinal disorders.
Table 1. Mechanism of action of SJZD in treatment of gastrointestinal disorders.
Regulating the intestinal flora
Microbiota plays a critical role as an important ecosystem in maintaining health by regulating immunity, metabolism, endocrinology, and providing protection against pathogen invasion. However, the intestinal flora is susceptible to dysbiosis caused by various external and internal factors, resulting in gastrointestinal dysfunction. Thus, improving the gut microbiota is essential for understanding the pathogenesis and treatment of gastrointestinal diseases.
Numerous studies have demonstrated that TCM can positively modulate the intestinal environment by influencing gut microbiota metabolites (Yue et al., 2019). To explore the effects of SJZD on gut microbiota, an analysis of ingredients and reaction pathways was conducted to elucidate its impact on gut microorganisms. The findings revealed a significant increase in the abundance of Bifidobacterium_pseudolongum with no observed decrease in the abundance of any other species following the administration of SJZD (Zhang Y. et al., 2022). Moreover, SJZD was utilized to investigate its potential anti-diarrheal effects in cases of antibiotic-associated diarrhea. The results revealed that SJZD effectively promoted the growth of beneficial flora by increasing the populations of Lactobacillus and Bifidobacterium, while simultaneously reducing the abundance of pathogenic Colibacillus in the intestines. These actions contributed to alleviating diarrhea symptoms, regulating the gut flora, and maintaining the integrity of intestinal villi (Guo et al., 2022). UC is associated with microbial dysregulation, making the modulation of intestinal flora a critical approach for its treatment. Research has shown that SJZD can reduce inflammation, restore colorectal barrier function, and enhance intestinal permeability in mice with UC by regulating the levels of gut microbiota, specifically Alistipes, Akkermansia, and Lachnospiraceae_NK4A136_group (Li et al., 2024). The non-polysaccharide components of SJZD, including flavonoids, saponins, and terpenoids, serve as the pharmacodynamic basis for its efficacy. These non-polysaccharides can alleviate gastrointestinal-nervous system dysfunction by modulating the microbiota-gut-metabolites axis, resulting in an increased relative abundance of beneficial probiotics such as Lactobacillus johnsonii and Lactobacillus_taiwanensis (Dong et al., 2024). These findings suggest that the regulation of intestinal flora is a vital mechanism through which SJZD exerts its therapeutic effects on gastrointestinal diseases.
Anti-inflammation
Inflammation plays a crucial role in the body’s immune defense, aiding in the eradication of pathogens, tissue repair, and regeneration (Grivennikov et al., 2010). However, chronic inflammation has been associated with the development and progression of several gastrointestinal disorders, including reflux esophagitis, gastritis, gastrointestinal cancer, inflammatory bowel disease, and diarrhea, among others. Consequently, anti-inflammatory interventions are essential in the treatment of these conditions.
Persistent inflammation of the gastric mucosa is recognized as a crucial contributor to the development and progression of gastritis. Research has demonstrated that SJZD effectively alleviates local gastric inflammation and reduces inflammation in peripheral blood leukocytes, thereby providing relief for chronic gastritis (Wang et al., 2020). Inflammation plays a pivotal role in the development of UC, which is characterized as a form of localized recurrence of intestinal inflammatory disease. A study has revealed that SJZD effectively enhances the inflammatory response induced by DSS in rats with UC. This beneficial effect is achieved through improvements in secretory IgA levels and the IL-2 level in the intestinal tissue (Yu et al., 2016). Subsequent investigations have provided additional evidence that SJZD effectively reduces the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and NO, thereby exerting its anti-inflammatory effect and alleviating ulcerative colitis. Among its components, R1, Rg2, and Rb3 demonstrate the most pronounced impact on the anti-inflammatory action (Kan et al., 2023). Neutrophil extracellular traps contain various inflammatory factors and proteins that play a crucial role in the intestinal immune imbalance associated with UC. These factors act as triggers for inflammatory signaling pathways, contributing to intestinal mucosal inflammation in UC (Drury et al., 2021). SJZD treats UC by reducing the levels of intestinal neutrophil extracellular traps, primarily targeting IL1B and TNF (Zhang et al., 2023). In conclusion, SJZD exhibits promising anti-inflammatory activity, making it a potential candidate for future exploration and discovery of novel anti-inflammatory agents.
Regulating the immune response
Gastrointestinal immune homeostasis plays a vital role in human physiology, as it maintains a delicate equilibrium between immune responses against invading pathogens and tolerance towards symbiotic bacteria. Intestinal diseases, including inflammatory bowel disease (Hu et al., 2023), gastrointestinal neoplasms (Mima et al., 2021), and gastritis (Yang and Hu, 2022), are closely associated with immune dysfunction. This association leads to various alterations in immune responses, impaired barrier function, and abnormal activation of immune cells within the gastrointestinal tract.
Spleen deficiency is frequently associated with immune dysfunction. Research indicates that one of the mechanisms by which SJZD exerts its spleen-tonifying and Qi-replenishing effects is through the modulation of immune function, specifically by enhancing the production of TNF-α and NO in macrophages (Gao et al., 2019). To investigate the role of SJZD in immune regulation, rats were administered SJZD. The results elucidated that SJZD enhances rat immune function by modulating the genetic expression of the JAK-STAT signaling pathway (Xiong and Qian, 2013). In other studies, SJZD was applied for treatment of post-operative ileus. Results demonstrated that SJZD has a moderating effect on immune function by improving the immunoglobulins, complement components, CD4+ and CD4+/CD8+, and reducing the TNF-α and CD8+ (Li et al., 2017). Furthermore, several studies investigated the immunomodulatory effects of polysaccharides present in SJZD. The findings revealed that these polysaccharides significantly enhanced macrophage phagocytic activity, stimulated the production of NO, and elevated the level of TNF-α (Ji et al., 2017). Similarly, another study demonstrated that a specific active polysaccharide known as S-3, found in SJZD, augmented intestinal immunity by upregulating the expression of T lymphocyte cells (Ma et al., 2021). These findings indicate that SJZD can target the immune system among its multiple targets.
Promoting intestinal mucosal restitution
The mucosal barrier assumes a pivotal role as the gastrointestinal tract’s primary defense mechanism, safeguarding against an array of dysfunctions (Sánchez de Medina et al., 2014). Impairment to this barrier constitutes a noteworthy driver of gastrointestinal disturbances, encompassing infections, gastrointestinal inflammatory diseases, and tumors (Dahiya and Nigam, 2023; Song et al., 2023). It is essential to preserve the integrity of the mucosal barrier to ensure optimal gastrointestinal function and impede the onset or progression of these disorders.
In a study examining the impact of SJZD on the restoration of intestinal function in a rabbit model following obstruction relief, the application of SJZD yielded significant outcomes. The findings demonstrated that SJZD effectively facilitated the restoration of intestinal function through multiple mechanisms, including reducing intestinal mucosal permeability, enhancing the secretion of intestinal mucins, and promoting the recovery of small intestine integrity (Yu et al., 2014). Furthermore, network pharmacology and experimental studies have demonstrated that the active components of SJZD possess the ability to repair intestinal epithelium injury induced by spleen deficiency syndrome through modulation of the FAK/PI3K/Akt signaling pathway (Ma et al., 2023). Polysaccharides are abundantly present in Chinese herbs and play a significant role in various physiological functions. As the principal component of SJZD, studies have revealed that these polysaccharides can promote intestinal restitution and provide protection against indomethacin-induced damage to intestinal epithelial cells by enhancing the expression of genes coding for ion channels and transporters (Liu et al., 2005). Intestinal epithelial cell migration is a crucial mechanism in the healing process of mucosal wounds. Experimental studies have demonstrated that the polysaccharides present in SJZD exert a positive effect on intestinal epithelial restitution by differentially regulating the cellular levels of STIM1 and STIM2. Specifically, these polysaccharides stimulate the translocation of STIM1, facilitate the association between STIM1 and TRPC1, and decrease the levels of both STIM1 and STIM2 (Shi et al., 2019). Additionally, another study has demonstrated that the polysaccharides in SJZD can alleviate the impairment of the intestinal epithelial cell barrier function induced by TNF-α by inhibiting NF-κB p65-mediated phosphorylation of myosin light chain and myosin light chain kinase (Lu et al., 2018). In summary, SJZD enhances intestinal mucosal restitution through various mechanisms, highlighting its therapeutic potential in gastrointestinal disorders.
Conclusion
Digestive diseases encompass a variety of conditions that have the potential to disrupt the normal digestive process, resulting in a spectrum of health effects that can range from mild to severe. It is crucial to emphasize the significance of early diagnosis, appropriate management, and regular monitoring in order to maintain optimal digestive health. Evidence has shown that TCM provides effective therapeutic outcomes for digestive diseases, with its multi-component, multi-target, and multi-pathway approach to overall regulation. As a classical prescription in TCM, SJZD has achieved good curative effects in gastrointestinal disorders in clinical practice due to its multicomponent and multitarget characteristics. In this review, we provide a comprehensive summary of the clinical research advancements surrounding the utilization of SJZD in the treatment of prevalent digestive system diseases. The therapeutic mechanism of SJZD in addressing these disorders is also analyzed, highlighting its significant role in regulating intestinal flora, mitigating inflammation, modulating the immune response, and facilitating mucosal repair.
Although significant progress has been made in exploring the mechanisms by which SJZD prevents and treats digestive diseases, several shortcomings persist. There are only a limited number of prospective, multi-center, and large-sample controlled studies available. Furthermore, as a compound prescription, current research on SJZD primarily examines its mechanisms of action from the perspective of the entire formula or analyzes the effects of individual Chinese herbs and herbal monomers. However, there is a notable lack of experimental studies investigating the interactions among the various components. Given the importance of SJZD in managing gastrointestinal disorders, further investigation into its clinical effects and underlying mechanisms is crucial. Future research should prioritize the clinical translation of SJZD, providing new insights and references for its application in the prevention and treatment of gastrointestinal inflammatory diseases, functional disorders, and tumors. Such efforts will enhance our understanding and optimize the therapeutic use of SJZD in gastrointestinal diseases.
Author contributions
LY: Funding acquisition, Writing–original draft, Writing–review and editing, Conceptualization, Data curation, Formal Analysis, Investigation. ZF: Writing–original draft, Writing–review and editing, Investigation. JZ: Data curation, Investigation, Writing–review and editing. XL: Data curation, Investigation, Writing–review and editing. BY: Data curation, Investigation, Writing–review and editing. HL: Data curation, Formal Analysis, Investigation, Writing–review and editing. FL: Conceptualization, Funding acquisition, Investigation, Visualization, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was financially supported by National Natural Science Foundation of China (82205033), Natural Science Foundation of Zhejiang Province (LQ22H270010), TCM Science and Technology project of Zhejiang Province (2023ZR071, 2024ZF041).
Acknowledgments
We would like to express our gratitude to Servier Medical Art for providing the visual medical illustrations that have greatly enhanced the clarity and presentation of our research findings. The authors would like to express their gratitude to Kimi, a generative AI developed by Moonshot AI, for its assistance in the grammatical proofreading of this manuscript. The specific version used is Kimi v2.0, and the technology was accessed through the official Moonshot AI platform.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
SJZD, Sijunzi Decoction; TCM, Traditional Chinese medicine; FD, Functional dyspepsia; IBS, Irritable bowel syndrome; UC, Ulcerative colitis.
References
Bailly, C. (2021). Atractylenolides, essential components of Atractylodes-based traditional herbal medicines: antioxidant, anti-inflammatory and anticancer properties. Eur. J. Pharmacol. 891, 173735. doi:10.1016/j.ejphar.2020.173735
Canakis, A., Haroon, M., and Weber, H. C. (2020). Irritable bowel syndrome and gut microbiota. Curr. Opin. Endocrinol. Diabetes Obes. 27, 28–35. doi:10.1097/MED.0000000000000523
Chen, J.-F., Wu, S.-W., Shi, Z.-M., and Hu, B. (2023a). Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. Chin. Med. 18, 14. doi:10.1186/s13020-023-00719-7
Chen, T., Zheng, X., Ouyang, L., Han, Z., Yang, Y., Gu, L., et al. (2023b). Six polyacetylenes from Atractylodes macrocephala Koidz and their anti-colon cancer activity. Fitoterapia 167, 105490. doi:10.1016/j.fitote.2023.105490
Chen, X., Yang, K., Yang, J., and Li, K. (2020). Meta-analysis of efficacy of sijunzi decoction combined with enteral nutrition for the treatment of gastric cancer. Nutr. Cancer 72, 723–733. doi:10.1080/01635581.2019.1653470
Cheng, H., Zhang, D., Wu, J., Liu, J., Tan, Y., Feng, W., et al. (2023). Atractylodes macrocephala Koidz. volatile oil relieves acute ulcerative colitis via regulating gut microbiota and gut microbiota metabolism. Front. Immunol. 14, 1127785. doi:10.3389/fimmu.2023.1127785
Choi, N.-R., Choi, W.-G., Lee, J.-H., Park, J., Kim, Y.-T., Das, R., et al. (2024a). Atractylodes macrocephala Koidz alleviates symptoms in zymosan-induced irritable bowel syndrome mouse model through TRPV1, NaV1.5, and NaV1.7 channel modulation. Nutrients 16, 1683. doi:10.3390/nu16111683
Choi, N.-R., Choi, W.-G., Zhu, A., Park, J., Kim, Y.-T., Hong, J., et al. (2024b). Exploring the therapeutic effects of Atractylodes macrocephala Koidz against human gastric cancer. Nutrients 16, 965. doi:10.3390/nu16070965
Chu, M. H. K., Wu, I. X. Y., Ho, R. S. T., Wong, C. H. L., Zhang, A. L., Zhang, Y., et al. (2018). Chinese herbal medicine for functional dyspepsia: systematic review of systematic reviews. Ther. Adv. Gastroenterol. 11, 1756284818785573. doi:10.1177/1756284818785573
Dahiya, D., and Nigam, P. S. (2023). Biotherapy using probiotics as therapeutic agents to restore the gut microbiota to relieve gastrointestinal tract inflammation, IBD, IBS and prevent induction of cancer. Int. J. Mol. Sci. 24, 5748. doi:10.3390/ijms24065748
Dai, L., Liu, Z., Zhou, W., Zhang, L., Miao, M., Wang, L., et al. (2024a). Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: a randomized, double-blind, placebo-controlled, multi-center clinical trial. Phytomedicine 129, 155636. doi:10.1016/j.phymed.2024.155636
Dai, Z., Tan, C., Wang, J., Wang, Q., Wang, Y., He, Y., et al. (2024b). Traditional Chinese medicine for gastric cancer: an evidence mapping. Phytother. Res. 38, 2707–2723. doi:10.1002/ptr.8155
Ding, P., Guo, Y., Wang, C., Chen, J., Guo, C., Liu, H., et al. (2022). A network pharmacology approach for uncovering the antitumor effects and potential mechanisms of the sijunzi decoction for the treatment of gastric cancer. Evid. Based Complement. Altern. Med. 2022, 9364313. doi:10.1155/2022/9364313
Dong, B., Peng, Y., Wang, M., Peng, C., and Li, X. (2024). Multi-omics integrated analyses indicated that non-polysaccharides of Sijunzi decoction ameliorated spleen deficiency syndrome via regulating microbiota-gut-metabolites axis and exerted synergistic compatibility. J. Ethnopharmacol. 331, 118276. doi:10.1016/j.jep.2024.118276
Dong, J., Na, Y., Hou, A., Zhang, S., Yu, H., Zheng, S., et al. (2023). A review of the botany, ethnopharmacology, phytochemistry, analysis method and quality control, processing methods, pharmacological effects, pharmacokinetics and toxicity of codonopsis radix. Front. Pharmacol. 14, 1162036. doi:10.3389/fphar.2023.1162036
Drury, B., Hardisty, G., Gray, R. D., and Ho, G. (2021). Neutrophil extracellular traps in inflammatory bowel disease: pathogenic mechanisms and clinical translation. Cell. Mol. Gastroenterology Hepatology 12, 321–333. doi:10.1016/j.jcmgh.2021.03.002
Du, J., Tao, Q., Liu, Y., Huang, Z., Jin, H., Lin, W., et al. (2022). Assessment of the targeted effect of Sijunzi decoction on the colorectal cancer microenvironment via the ESTIMATE algorithm. PLoS One 17, e0264720. doi:10.1371/journal.pone.0264720
Feuerstein, J. D., Moss, A. C., and Farraye, F. A. (2019). Ulcerative colitis. Mayo Clin. Proc. 94, 1357–1373. doi:10.1016/j.mayocp.2019.01.018
Ford, A. C., Mahadeva, S., Carbone, M. F., Lacy, B. E., and Talley, N. J. (2020). Functional dyspepsia. Lancet 396, 1689–1702. doi:10.1016/S0140-6736(20)30469-4
Gan, D., Xu, A., Du, H., and Ye, Y. (2017). Chinese classical formula sijunzi decoction and chronic atrophic gastritis: evidence for treatment approach? Evid. Based Complement. Altern. Med. 2017, 9012929. doi:10.1155/2017/9012929
Gao, B., Peng, Y., Peng, C., Zhang, Y., and Li, X. (2019). A comparison of characterization and its actions on immunocompetent cells of polysaccharides from sijunzi decoction. Evid. Based Complement. Altern. Med. 2019, 9860381. doi:10.1155/2019/9860381
Gao, B., Wang, R., Peng, Y., and Li, X. (2018). Effects of a homogeneous polysaccharide from Sijunzi decoction on human intestinal microbes and short chain fatty acids in vitro. J. Ethnopharmacol. 224, 465–473. doi:10.1016/j.jep.2018.06.006
Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883–899. doi:10.1016/j.cell.2010.01.025
Gu, S., Li, L., Huang, H., Wang, B., and Zhang, T. (2019). Antitumor, antiviral, and anti-inflammatory efficacy of essential oils from Atractylodes macrocephala Koidz. Produced with different processing methods. Molecules 24, 2956. doi:10.3390/molecules24162956
Guo, X., Yan, Z., Wang, J., Fan, X., Kang, J., Niu, R., et al. (2022). Effect of traditional Chinese medicine (TCM) and its fermentation using Lactobacillus plantarum on ceftriaxone sodium-induced dysbacteriotic diarrhea in mice. Chin. Med. 17, 20. doi:10.1186/s13020-022-00575-x
Halama, N., and Haberkorn, U. (2020). The unmet needs of the diagnosis, staging, and treatment of gastrointestinal tumors. Semin. Nucl. Med. 50, 389–398. doi:10.1053/j.semnuclmed.2020.06.003
Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2024). Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47–53. doi:10.1016/j.jncc.2024.01.006
Hong, X., Li, H., Lin, Y., Luo, L., Xu, W., Kang, J., et al. (2024). Efficacy and potential therapeutic mechanism of Weiwei decoction on Spasmolytic polypeptide-expressing metaplasia in Helicobacter pylori-infected and Atp4a-knockout mice. J. Ethnopharmacol. 319, 117062. doi:10.1016/j.jep.2023.117062
Hu, C., Liao, S., Lv, L., Li, C., and Mei, Z. (2023). Intestinal immune imbalance is an alarm in the development of IBD. Mediat. Inflamm. 2023, 1073984. doi:10.1155/2023/1073984
Huang, K.-Y., Wang, F.-Y., Lv, M., Ma, X.-X., Tang, X.-D., and Lv, L. (2023). Irritable bowel syndrome: epidemiology, overlap disorders, pathophysiology and treatment. World J. Gastroenterol. 29, 4120–4135. doi:10.3748/wjg.v29.i26.4120
Huang, X., and Shao, S. (2024). Meta-analysis of modified Sijunzi decoction for the treatment of chronic atrophic gastritis. Medicine 103, e37648. doi:10.1097/MD.0000000000037648
Hung, K.-F., Hsu, C.-P., Chiang, J.-H., Lin, H.-J., Kuo, Y.-T., Sun, M.-F., et al. (2017). Complementary Chinese herbal medicine therapy improves survival of patients with gastric cancer in Taiwan: a nationwide retrospective matched-cohort study. J. Ethnopharmacol. 199, 168–174. doi:10.1016/j.jep.2017.02.004
Ji, Y., Wang, R., Peng, Y., Peng, C., and Li, X. (2017). Purification, preliminary characterization, and immunological activity of polysaccharides from crude drugs of sijunzi formula. Evid. Based Complement. Altern. Med. 2017, 2170258. doi:10.1155/2017/2170258
Jia, J., Qin, Y., Zhang, L., Guo, C., Wang, Y., Yue, X., et al. (2018). Sijunzi decoction-treated rat serum induces apoptosis of side population cells in gastric carcinoma. Exp. Ther. Med. 15, 1718–1727. doi:10.3892/etm.2017.5560
Jiang, M., Zhao, S., Yang, S., Lin, X., He, X., Wei, X., et al. (2020). An “essential herbal medicine”-licorice: a review of phytochemicals and its effects in combination preparations. J. Ethnopharmacol. 249, 112439. doi:10.1016/j.jep.2019.112439
Jie, Y., He, W., Yang, X., and Chen, W. (2017). Krüppel-like factor 4 acts as a potential therapeutic target of Sijunzi decoction for treatment of colorectal cancer. Cancer Gene Ther. 24, 361–366. doi:10.1038/cgt.2017.25
Jin, X., Che, D., Zhang, Z., Yan, H., Jia, Z., and Jia, X. (2016). Ginseng consumption and risk of cancer: a meta-analysis. J. Ginseng Res. 40, 269–277. doi:10.1016/j.jgr.2015.08.007
Kan, H., Zhang, D., Chen, W., Wang, S., He, Z., Pang, S., et al. (2023). Identification of anti-inflammatory components in Panax ginseng of Sijunzi Decoction based on spectrum-effect relationship. Chin. Herb. Med. 15, 123–131. doi:10.1016/j.chmed.2022.04.003
Kucharzik, T., Koletzko, S., Kannengiesser, K., and Dignass, A. (2020). Ulcerative colitis—diagnostic and therapeutic algorithms. Dtsch. Arztebl Int. 117, 564–574. doi:10.3238/arztebl.2020.0564
Lacy, B. E., Chase, R. C., and Cangemi, D. J. (2023). The treatment of functional dyspepsia: present and future. Expert Rev. Gastroenterol. Hepatol. 17, 9–20. doi:10.1080/17474124.2023.2162877
Lan, K., Yang, H., Zheng, J., Hu, H., Zhu, T., Zou, X., et al. (2023). Poria cocos oligosaccharides ameliorate dextran sodium sulfate-induced colitis mice by regulating gut microbiota dysbiosis. Food Funct. 14, 857–873. doi:10.1039/d2fo03424g
Li, F., Liu, B., Li, T., Wu, Q., Xu, Z., Gu, Y., et al. (2020). Review of Constituents and Biological Activities of Triterpene Saponins from Glycyrrhizae Radix et Rhizoma and Its Solubilization Characteristics. Molecules 25, 3904. doi:10.3390/molecules25173904
Li, H., Pu, X., Lin, Y., Yu, X., Li, J., Bo, L., et al. (2024). Sijunzi decoction alleviates inflammation and intestinal epithelial barrier damage and modulates the gut microbiota in ulcerative colitis mice. Front. Pharmacol. 15, 1360972. doi:10.3389/fphar.2024.1360972
Li, L., Zou, C., Zhou, Z., and Yu, X. (2017). Effects of herbal medicine Sijunzi decoction on rabbits after relieving intestinal obstruction. Braz J. Med. Biol. Res. 50, e6331. doi:10.1590/1414-431X20176331
Li, X., Chen, W., Miao, L., Sun, H., Gao, X., Guo, S., et al. (2022a). Antitumor effect of Si-Jun-Zi decoction on SGC7901 gastric cancer cells by CMTM2 activation. Evid. Based Complement. Altern. Med. 2022, 4675815. doi:10.1155/2022/4675815
Li, Y., Chen, Y., Zeng, Y., Dong, J., Li, C., Jia, Y., et al. (2021). Enteral nutrition combined with improved-sijunzi decoction shows positive effect in precachexia cancer patients: a retrospective analysis. Evid. Based Complement. Altern. Med. 2021, 7357521. doi:10.1155/2021/7357521
Li, Y.-J., Liao, L.-L., Liu, P., Tang, P., Wang, H., and Peng, Q.-H. (2022b). Sijunzi decoction inhibits stemness by suppressing β-catenin transcriptional activity in gastric cancer cells. Chin. J. Integr. Med. 28, 702–710. doi:10.1007/s11655-021-3314-9
Liu, C., Wang, S., Xiang, Z., Xu, T., He, M., Xue, Q., et al. (2022). The chemistry and efficacy benefits of polysaccharides from Atractylodes macrocephala Koidz. Front. Pharmacol. 13, 952061. doi:10.3389/fphar.2022.952061
Liu, L., Han, L., Wong, D. Y. L., Yue, P. Y. K., Ha, W. Y., Hu, Y. H., et al. (2005). Effects of Si-Jun-Zi decoction polysaccharides on cell migration and gene expression in wounded rat intestinal epithelial cells. Br. J. Nutr. 93, 21–29. doi:10.1079/bjn20041295
Liu, N., Li, J., Wang, Y., and Zhang, S. (2023). Different therapies of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome: a network meta-analysis of double-blinded, placebo-controlled trials. J. Ethnopharmacol. 317, 116672. doi:10.1016/j.jep.2023.116672
Lu, Y., Li, L., Zhang, J.-W., Zhong, X.-Q., Wei, J.-A., and Han, L. (2018). Total polysaccharides of the Sijunzi decoction attenuate tumor necrosis factor-α-induced damage to the barrier function of a Caco-2 cell monolayer via the nuclear factor-κB-myosin light chain kinase-myosin light chain pathway. World J. Gastroenterol. 24, 2867–2877. doi:10.3748/wjg.v24.i26.2867
Lu, Y., Lin, H., Zhang, J., Wei, J., Sun, J., and Han, L. (2017). Sijunzi Decoction attenuates 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats and ameliorates TNBS-induced claudin-2 damage via NF-κB pathway in Caco2 cells. BMC Complement. Altern. Med. 17, 35. doi:10.1186/s12906-016-1549-3
Luan, F., Ji, Y., Peng, L., Liu, Q., Cao, H., Yang, Y., et al. (2021). Extraction, purification, structural characteristics and biological properties of the polysaccharides from Codonopsis pilosula: a review. Carbohydr. Polym. 261, 117863. doi:10.1016/j.carbpol.2021.117863
Ma, P., Peng, C., Peng, Y., Fan, L., Chen, X., and Li, X. (2023). A mechanism of Sijunzi decoction on improving intestinal injury with spleen deficiency syndrome and the rationality of its compatibility. J. Ethnopharmacol. 306, 116088. doi:10.1016/j.jep.2022.116088
Ma, P., Peng, Y., Zhao, L., Liu, F., and Li, X. (2021). Differential effect of polysaccharide and nonpolysaccharide components in Sijunzi decoction on spleen deficiency syndrome and their mechanisms. Phytomedicine 93, 153790. doi:10.1016/j.phymed.2021.153790
Mima, K., Kosumi, K., Baba, Y., Hamada, T., Baba, H., and Ogino, S. (2021). The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. Hum. Genet. 140, 725–746. doi:10.1007/s00439-020-02235-2
Mishra, R., Dhawan, P., Srivastava, A. S., and Singh, A. B. (2020). Inflammatory bowel disease: therapeutic limitations and prospective of the stem cell therapy. World J. Stem Cells 12, 1050–1066. doi:10.4252/wjsc.v12.i10.1050
Ni, B., Song, X., Shi, B., Wang, J., Sun, Q., Wang, X., et al. (2022). Research progress of ginseng in the treatment of gastrointestinal cancers. Front. Pharmacol. 13, 1036498. doi:10.3389/fphar.2022.1036498
Oka, P., Parr, H., Barberio, B., Black, C. J., Savarino, E. V., and Ford, A. C. (2020). Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 908–917. doi:10.1016/S2468-1253(20)30217-X
Park, J., and Cheon, J. H. (2021). Incidence and prevalence of inflammatory bowel disease across Asia. Yonsei Med. J. 62, 99–108. doi:10.3349/ymj.2021.62.2.99
Peery, A. F., Crockett, S. D., Barritt, A. S., Dellon, E. S., Eluri, S., Gangarosa, L. M., et al. (2015). Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 149, 1731–1741. doi:10.1053/j.gastro.2015.08.045
Pilkington, K., Wieland, L. S., Teng, L., Jin, X. Y., Storey, D., and Liu, J. P. (2022). Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database Syst. Rev. 11, CD012053. doi:10.1002/14651858.CD012053.pub2
Qian, C., Xu, Z., Chen, L., Wang, Y., and Yao, J. (2020). Long noncoding RNA LINC01391 restrained gastric cancer aerobic glycolysis and tumorigenesis via targeting miR-12116/CMTM2 axis. J. Cancer 11, 6264–6276. doi:10.7150/jca.48365
Qin, F., Liu, J.-Y., and Yuan, J.-H. (2013). Chaihu-Shugan-San, an oriental herbal preparation, for the treatment of chronic gastritis: a meta-analysis of randomized controlled trials. J. Ethnopharmacol. 146, 433–439. doi:10.1016/j.jep.2013.01.029
Qu, L., Tan, W., Yang, J., Lai, L., Liu, S., Wu, J., et al. (2020). Combination compositions composed of l-glutamine and Si-Jun-Zi-Tang might Be a preferable choice for 5-fluorouracil-induced intestinal mucositis: an exploration in a mouse model. Front. Pharmacol. 11, 918. doi:10.3389/fphar.2020.00918
Quan, P., Yu, L., Yang, Z., Lei, P., Wan, C., and Chen, Y. (2018). Development and validation of quality of life instruments for chronic diseases—chronic gastritis version 2 (QLICD-CG V2.0). PLoS One 13, e0206280. doi:10.1371/journal.pone.0206280
Sánchez de Medina, F., Romero-Calvo, I., Mascaraque, C., and Martínez-Augustin, O. (2014). Intestinal inflammation and mucosal barrier function. Inflamm. Bowel Dis. 20, 2394–2404. doi:10.1097/MIB.0000000000000204
Shang, L., Wang, Y., Li, J., Zhou, F., Xiao, K., Liu, Y., et al. (2023). Mechanism of Sijunzi Decoction in the treatment of colorectal cancer based on network pharmacology and experimental validation. J. Ethnopharmacol. 302, 115876. doi:10.1016/j.jep.2022.115876
Shen, H., Zhang, S., Zhao, W., Ren, S., Ke, X., Gu, Q., et al. (2021). Randomised clinical trial: efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis. Biomed. Pharmacother. 139, 111580. doi:10.1016/j.biopha.2021.111580
Shi, Y., Zhu, H., Li, R., Wang, D., Zhu, Y., Hu, L., et al. (2019). Effect of polysaccharides from Sijunzi decoction on Ca2+ related regulators during intestinal mucosal restitution. Phytomedicine 58, 152880. doi:10.1016/j.phymed.2019.152880
Singh, R., Zogg, H., Ghoshal, U. C., and Ro, S. (2022). Current treatment options and therapeutic insights for gastrointestinal dysmotility and functional gastrointestinal disorders. Front. Pharmacol. 13, 808195. doi:10.3389/fphar.2022.808195
Sipponen, P., and Maaroos, H.-I. (2015). Chronic gastritis. Scand. J. Gastroenterol. 50, 657–667. doi:10.3109/00365521.2015.1019918
Song, C., Chai, Z., Chen, S., Zhang, H., Zhang, X., and Zhou, Y. (2023). Intestinal mucus components and secretion mechanisms: what we do and do not know. Exp. Mol. Med. 55, 681–691. doi:10.1038/s12276-023-00960-y
Speciality Committee of Digestive Diseases, Chinese Association of Integrative Medicine (2011). Consensus on functional dyspepsia by integrative medicine (2010). Zhongguo Zhong Xi Yi Jie He Za Zhi 31, 1545–1549.
Tan, N., Gwee, K. A., Tack, J., Zhang, M., Li, Y., Chen, M., et al. (2020). Herbal medicine in the treatment of functional gastrointestinal disorders: a systematic review with meta-analysis. J. Gastroenterol. Hepatol. 35, 544–556. doi:10.1111/jgh.14905
Tang, M., Zhang, W., Qin, W., Zou, C., Yan, Y., He, B., et al. (2022). Association between oral Chinese herbal medicine and recurrence and metastasis in patients with stages II and III colorectal cancer: a cohort study in China. Evid. Based Complement. Altern. Med. 2022, 8529395. doi:10.1155/2022/8529395
Thanikachalam, K., and Khan, G. (2019). Colorectal cancer and nutrition. Nutrients 11, 164. doi:10.3390/nu11010164
Thrift, A. P., Wenker, T. N., and El-Serag, H. B. (2023). Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat. Rev. Clin. Oncol. 20, 338–349. doi:10.1038/s41571-023-00747-0
Tian, G., Wu, C., Li, J., Liang, B., Zhang, F., Fan, X., et al. (2019). Network pharmacology based investigation into the effect and mechanism of Modified Sijunzi Decoction against the subtypes of chronic atrophic gastritis. Pharmacol. Res. 144, 158–166. doi:10.1016/j.phrs.2019.04.012
Wang, F., Lau, J. K. C., and Yu, J. (2021a). The role of natural killer cell in gastrointestinal cancer: killer or helper. Oncogene 40, 717–730. doi:10.1038/s41388-020-01561-z
Wang, H., Luo, Y., Chu, Z., Ni, T., Ou, S., Dai, X., et al. (2022). Poria acid, triterpenoids extracted from Poria cocos, inhibits the invasion and metastasis of gastric cancer cells. Molecules 27, 3629. doi:10.3390/molecules27113629
Wang, T., Feng, Y., Wang, H., Huo, G., Cai, Y., Wang, L., et al. (2020). The mechanisms of sijunzi decoction in the treatment of chronic gastritis revealed by network pharmacology. Evid. Based Complement. Altern. Med. 2020, 8850259. doi:10.1155/2020/8850259
Wang, X., Pan, S., Chen, L., Liang, C., Zhu, Y., Zhou, K., et al. (2024). Sijunzi decoction enhances sensitivity of colon cancer cells to NK cell destruction by modulating P53 expression. J. Ethnopharmacol. 329, 118115. doi:10.1016/j.jep.2024.118115
Wang, Y., Huang, Y., Chase, R. C., Li, T., Ramai, D., Li, S., et al. (2023). Global burden of digestive diseases: a systematic analysis of the global burden of diseases study, 1990 to 2019. Gastroenterology 165, 773–783.e15. doi:10.1053/j.gastro.2023.05.050
Wang, Y., Liu, B., Fu, X., Tong, T., and Yu, Z. (2021b). Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials. BMC Complement. Med. Ther. 21, 11. doi:10.1186/s12906-020-03176-z
Wu, B., and Xuan, Z. (2007). Progress in research on applying Sijunzi Decoction in treating digestive malignant tumor. Chin. J. Integr. Med. 13, 156–159. doi:10.1007/s11655-007-0156-z
Wu, T.-H., Chen, I.-C., and Chen, L.-C. (2010). Antacid effects of Chinese herbal prescriptions assessed by a modified artificial stomach model. World J. Gastroenterol. 16, 4455–4459. doi:10.3748/wjg.v16.i35.4455
Wu, Y., Zheng, Y., Wang, X., Tang, P., Guo, W., Ma, H., et al. (2023). Ginseng-containing sijunzi decoction ameliorates ulcerative colitis by orchestrating gut homeostasis in microbial modulation and intestinal barrier integrity. Am. J. Chin. Med. 51, 677–699. doi:10.1142/S0192415X23500325
Xia, X., Xie, Y., Chen, Q., Ding, D., Wang, Z., Xu, Y., et al. (2022). Cocultivation of Chinese prescription and intestine microbiota: SJZD alleviated the major symptoms of IBS-D subjects by tuning neurotransmitter metabolism. Front. Endocrinol. (Lausanne) 13, 1053103. doi:10.3389/fendo.2022.1053103
Xiang, X., Cao, N., Chen, F., Qian, L., Wang, Y., Huang, Y., et al. (2020). Polysaccharide of Atractylodes macrocephala Koidz (PAMK) alleviates cyclophosphamide-induced immunosuppression in mice by upregulating CD28/IP3R/plcγ-1/AP-1/NFAT signal pathway. Front. Pharmacol. 11, 529657. doi:10.3389/fphar.2020.529657
Xiao, H.-T., Zhong, L., Tsang, S.-W., Lin, Z.-S., and Bian, Z.-X. (2015). Traditional Chinese medicine formulas for irritable bowel syndrome: from ancient wisdoms to scientific understandings. Am. J. Chin. Med. 43, 1–23. doi:10.1142/S0192415X15500019
Xiong, B., and Qian, H. (2013). Effects of Sijunzi decoction and Yupingfeng powder on expression of janus kinase-signal transducer and activator of transcription signal pathway in the brain of spleen-deficiency model rats. J. Tradit. Chin. Med. 33, 78–84. doi:10.1016/s0254-6272(13)60105-3
Yan, J., Cui, Y., and Ren, B. (2023). A meta-analysis of modified sijunzi decoction combined with Tongxie Yaofang in the treatment of IBS-D. Front. Med. Sci. Res. 5. doi:10.25236/FMSR.2023.050917
Yang, H., and Hu, B. (2022). Immunological perspective: Helicobacter pylori infection and gastritis. Mediat. Inflamm. 2022, 2944156. doi:10.1155/2022/2944156
Yang, L., Li, J., Hu, Z., Fan, X., Cai, T., Zhou, H., et al. (2020a). A systematic review of the mechanisms underlying treatment of gastric precancerous lesions by traditional Chinese medicine. Evidence-Based Complementary Altern. Med. 2020, 9154738. doi:10.1155/2020/9154738
Yang, P., Yang, H., Zhou, H., Li, Q., Wei, S., Wang, Q., et al. (2022). Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition. Chin. Med. 17, 104. doi:10.1186/s13020-022-00663-y
Yang, S., Zhang, J., Yan, Y., Yang, M., Li, C., Li, J., et al. (2020b). Network pharmacology-based strategy to investigate the pharmacologic mechanisms of Atractylodes macrocephala Koidz. For the treatment of chronic gastritis. Front. Pharmacol. 10, 1629. doi:10.3389/fphar.2019.01629
Yang, X., Lu, S., Feng, Y., Cao, C., Zhang, Y., and Cheng, S. (2023). Characteristics and properties of a polysaccharide isolated from Wolfiporia cocos as potential dietary supplement for IBS. Front. Nutr. 10, 1119583. doi:10.3389/fnut.2023.1119583
Yan-Rui, W., Xue-Er, Y., Mao-Yu, D., Ya-Ting, L., Bo-Heng, L., Miao-Jie, Z., et al. (2024). Research on the signaling pathway and the related mechanism of traditional Chinese medicine intervention in chronic gastritis of the “inflammation-cancer transformation.”. Front. Pharmacol. 15, 1338471. doi:10.3389/fphar.2024.1338471
Yu, W., Lu, B., Zhang, H., Zhang, Y., and Yan, J. (2016). Effects of the Sijunzi decoction on the immunological function in rats with dextran sulfate-induced ulcerative colitis. Biomed. Rep. 5, 83–86. doi:10.3892/br.2016.678
Yu, X., Cui, Z., Zhou, Z., Shan, T., Li, D., and Cui, N. (2014). Si-Jun-Zi decoction treatment promotes the restoration of intestinal function after obstruction by regulating intestinal homeostasis. Evid. Based Complement. Altern. Med. 2014, 928579. doi:10.1155/2014/928579
Yue, S.-J., Wang, W.-X., Yu, J.-G., Chen, Y.-Y., Shi, X.-Q., Yan, D., et al. (2019). Gut microbiota modulation with traditional Chinese medicine: a system biology-driven approach. Pharmacol. Res. 148, 104453. doi:10.1016/j.phrs.2019.104453
Zhang, D., Duan, S., He, Z., Zhu, Z., Li, Z., Yi, Q., et al. (2023). Sijunzi decoction targets IL1B and TNF to reduce neutrophil extracellular traps (NETs) in ulcerative colitis: evidence from silicon prediction and experiment validation. Drug Des. Devel Ther. 17, 3103–3128. doi:10.2147/DDDT.S428814
Zhang, M., Sun, Y., Lv, Z., Lin, H., Han, M., and Yang, L. (2024). The adaptive mechanism of ginseng rhizomes in response to habitat changes. Curr. Issues Mol. Biol. 46, 12260–12278. doi:10.3390/cimb46110728
Zhang, S., Luo, H., Tan, D., Peng, B., Zhong, Z., and Wang, Y. (2022a). Holism of Chinese herbal medicine prescriptions for inflammatory bowel disease: a review based on clinical evidence and experimental research. Phytomedicine 102, 154202. doi:10.1016/j.phymed.2022.154202
Zhang, Y., Zhang, D., Bai, X., Chen, Y., Qiu, Q., Shang, X., et al. (2022b). The impact of Traditional Chinese Medicine on mouse gut microbiota abundances and interactions based on Granger causality and pathway analysis. Front. Microbiol. 13, 980082. doi:10.3389/fmicb.2022.980082
Zhao, L., Zhang, T., and Zhang, K. (2024). Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system. Front. Immunol. 15, 1353614. doi:10.3389/fimmu.2024.1353614
Zhao, L., Zhang, Y., Li, Y., Li, C., Shi, K., Zhang, K., et al. (2022). Therapeutic effects of ginseng and ginsenosides on colorectal cancer. Food Funct. 13, 6450–6466. doi:10.1039/d2fo00899h
Zheng, S., Xue, T., Wang, B., Guo, H., and Liu, Q. (2022). Chinese medicine in the treatment of ulcerative colitis: the mechanisms of signaling pathway regulations. Am. J. Chin. Med. 50, 1781–1798. doi:10.1142/S0192415X22500756
Zhou, J.-Y., Chen, M., Wu, C.-E., Zhuang, Y.-W., Chen, Y.-G., and Liu, S.-L. (2019). The modified Si-Jun-Zi Decoction attenuates colon cancer liver metastasis by increasing macrophage cells. BMC Complement. Altern. Med. 19, 86. doi:10.1186/s12906-019-2498-4
Zhu, Y., Ma, R., Cheng, W., Qin, M., Guo, W., Qi, Y., et al. (2024). Sijunzi decoction ameliorates gastric precancerous lesions via regulating oxidative phosphorylation based on proteomics and metabolomics. J. Ethnopharmacol. 318, 116925. doi:10.1016/j.jep.2023.116925
Keywords: Sijunzi decoction (SJZD), gastrointestinal disorders, traditional Chinese, functional dyspepsia, irritable bowel syndrome, tumor
Citation: Yang L, Fang Z, Zhu J, Li X, Yang B, Liu H and Lou F (2025) The potential of Sijunzi decoction in the fight against gastrointestinal disorders: a review. Front. Pharmacol. 16:1464498. doi: 10.3389/fphar.2025.1464498
Received: 14 July 2024; Accepted: 03 February 2025;
Published: 04 March 2025.
Edited by:
Daniele Maria-Ferreira, Instituto de Pesquisa Pelé Pequeno Príncipe, BrazilReviewed by:
Fengjie Sun, Georgia Gwinnett College, United StatesJu Wang, Sapienza University of Rome, Italy
Copyright © 2025 Yang, Fang, Zhu, Li, Yang, Liu and Lou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Feiyan Lou, bGZ5MTM0ODYzNzEzODkyMDIzQDE2My5jb20=